Processa Pharmaceuticals to participate in upcoming investor conferences
Processa Pharmaceuticals said it will participate in two upcoming investor conferences.
VERO BEACH, FL, Sept.
01, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc.
NASDAQ:PCSA, a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases, today announced its participation in two upcoming investor conf…